Investor Presentation Q1 2023

14 Investor presentation First three months of 2023 Financial outlook for 2023 Sales growth - at CER Expectations 4 May 2023 24% to 30% Expectations 1 Feb 2023 13% to 19% Sales growth - reported Operating profit growth - at CER Operating profit growth - reported Around 6 percentage points lower 28% to 34% Around 9 percentage points lower Around 4 percentage points lower 13% to 19% Around 5 percentage points lower Financial items (net) Effective tax rate Free cash flow Gain of around DKK 3.0 billion Gain of around DKK 2.4 billion 19% to 21% DKK 66 to 74 billion 19% to 21% DKK 60 to 68 billion The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 27 April 2023 CER: Constant exchange rates Note: Changes since last highlighted in bold Novo NordiskⓇ

View entire presentation